Latest News

12345678910
Here's How Much You Would Have Made Owning Super Micro Computer Stock In The Last 10 Yearsbenzinga.com
Via Benzinga · February 24, 2026
MercadoLibre Stock Climbs After Posting Mixed Q4 Results, Strong E-Commerce Growthinvestors.com
MercadoLibre stock gained after the Latin America-focused e-commerce company reported fourth-quarter results.
Via Investor's Business Daily · February 24, 2026
Merit Medical Systems (NASDAQ:MMSI) Exceeds Q4 CY2025 Expectations
Medical device company Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue in Q4 CY2025, with sales up 10.9% year on year to $393.9 million. The company’s full-year revenue guidance of $1.62 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $0.93 per share was 2.5% below analysts’ consensus estimates.
Via StockStory · February 24, 2026
Verra Mobility (NASDAQ:VRRM) Beats Q4 CY2025 Sales Expectations But Stock Drops
Traffic solutions company Verra Mobility (NYSE:VRRM) announced better-than-expected revenue in Q4 CY2025, with sales up 16.4% year on year to $257.9 million. The company expects the full year’s revenue to be around $1.03 billion, close to analysts’ estimates. Its non-GAAP profit of $0.30 per share was 4.1% below analysts’ consensus estimates.
Via StockStory · February 24, 2026
TransMedics Group Earnings Review: Q4 Summarybenzinga.com
Via Benzinga · February 24, 2026
Earnings Breakdown: Sun Communities Q4benzinga.com
Via Benzinga · February 24, 2026
TransMedics Group Earnings Report: Q4 Overviewbenzinga.com
Via Benzinga · February 24, 2026
Huron (NASDAQ:HURN) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
Professional services firm Huron Consulting Group (NASDAQ:HURN) missed Wall Street’s revenue expectations in Q4 CY2025, but sales rose 10.7% year on year to $442 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.82 billion at the midpoint. Its non-GAAP profit of $2.17 per share was 11.3% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
NexGen Energy’s Rook I Project Emerges as a Key Source in the Next Uranium Supply Wavefool.com
MMCAP International increased its stake in NexGen Energy during the fourth quarter, deepening exposure to the company’s Rook I uranium project in Canada. As governments extend reactor lifespans and reconsider nuclear expansion, attention is turning to future uranium supply and how quickly projects like Rook I can begin production.
Via The Motley Fool · February 24, 2026
Tesla To Hike Price On Cheapest Cybertruck Variant After Feb. 28stocktwits.com
The base version of the Cybertruck, called the Dual Motor AWD variant, starts at $59,990 now.
Via Stocktwits · February 24, 2026
UFP Technologies Q4 Earnings Summary & Key Takeawaysbenzinga.com
Via Benzinga · February 24, 2026
Insights into Everus Construction Group Q4 Earningsbenzinga.com
Via Benzinga · February 24, 2026
Sun Communities Earnings Review: Q4 Summarysun-com
Via Benzinga · February 24, 2026
SPX Technologies (NYSE:SPXC) Exceeds Q4 CY2025 Expectations
Infrastructure equipment supplier SPX Technologies (NYSE:SPXC) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 19.4% year on year to $637.3 million. The company’s full-year revenue guidance of $2.57 billion at the midpoint came in 3.8% above analysts’ estimates. Its non-GAAP profit of $1.88 per share was 0.7% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
eXp World (NASDAQ:EXPI) Posts Better-Than-Expected Sales In Q4 CY2025
Real estate technology company eXp World (NASDAQ:EXPI) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 8.5% year on year to $1.19 billion. Its GAAP loss of $0.08 per share was significantly below analysts’ consensus estimates.
Via StockStory · February 24, 2026
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indicationsstocktwits.com
Theriva Biologics licenses SYN-020 to Rasayana for $300k upfront and up to $38M in future milestones.
Via Stocktwits · February 24, 2026
Invest $10,000 in This Dividend Stock for $530 in Passive Incomehttps://www.fool.ca/2026/02/24/invest-10000-in-this-dividend-stock-for-530-in-passive-income/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=267e31e8-479e-415d-b076-3807db0d1e36
Given its solid fundamentals, strong balance sheet, steady cash flow generation, and promising growth outlook, Whitecap Resources appears well-positioned to appeal to income-focused investors seeking both stability and long-term return potential.
Via The Motley Fool · February 24, 2026
Luxfer Holdings Q4 Earnings Assessmentbenzinga.com
Via Benzinga · February 24, 2026
$100 Invested In Energy Transfer 5 Years Ago Would Be Worth This Much Todaybenzinga.com
Via Benzinga · February 24, 2026
1 Magnificent Canadian Dividend Stock Down 4% to Hold for Decadeshttps://www.fool.ca/2026/02/24/1-magnificent-canadian-dividend-stock-down-4-to-hold-for-decades/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=5d22c049-0de4-4325-bcaa-e45f56030db1
A top Canadian dividend stock is trading 4% lower, creating a rare opportunity for long‑term investors.
Via The Motley Fool · February 24, 2026
UFP Technologies (NASDAQ:UFPT) Posts Q4 CY2025 Sales In Line With Estimates
Medical products company UFP Technologies (NASDAQ:UFPT) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 3.4% year on year to $148.9 million. Its non-GAAP profit of $2.44 per share was 9.2% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026stocktwits.com
Theriva Biologics to present VCN-01 Phase 1 and preclinical data for retinoblastoma at APAO 2026.
Via Stocktwits · February 24, 2026
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sectormarketbeat.com
Via MarketBeat · February 24, 2026
New Mountain Finance Q4 Earnings Summary & Key Takeawaysbenzinga.com
Via Benzinga · February 24, 2026
Astronics (NASDAQ:ATRO) Exceeds Q4 CY2025 Expectations
Aerospace and defense technology solutions provider Astronics Corporation (NASDAQ:ATRO) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 15.1% year on year to $240.1 million. On the other hand, next quarter’s revenue guidance of $225 million was less impressive, coming in 3.3% below analysts’ estimates. Its non-GAAP profit of $0.75 per share was 25% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Axon (NASDAQ:AXON) Beats Expectations in Strong Q4 CY2025, Stock Jumps 15.1%
Self defense company AXON (NASDAQ:AXON) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 38.5% year on year to $796.7 million. The company’s full-year revenue guidance of $6 billion at the midpoint came in 74.4% above analysts’ estimates. Its non-GAAP profit of $2.15 per share was 34.5% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Axon Enterprise Tops Q4 Estimates, Issues Strong Guidance As Momentum Acceleratesbenzinga.com
Axon Enterprise Inc (NASDAQ:AXON) reports financial results for the fourth quarter after the bell on Tuesday.
Via Benzinga · February 24, 2026
First Solar (NASDAQ:FSLR) Beats Q4 CY2025 Sales Expectations But Stock Drops 10.2%
Solar panel manufacturer First Solar (NASDAQ:FSLR) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11.1% year on year to $1.68 billion. On the other hand, the company’s full-year revenue guidance of $5.05 billion at the midpoint came in 17.4% below analysts’ estimates. Its GAAP profit of $4.84 per share was 6.3% below analysts’ consensus estimates.
Via StockStory · February 24, 2026
HP (NYSE:HPQ) Exceeds Q4 CY2025 Expectations But Stock Drops
Personal computing and printing company HP (NYSE:HPQ) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.9% year on year to $14.44 billion. Its non-GAAP profit of $0.81 per share was 5.3% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
CAVA’s (NYSE:CAVA) Q4 CY2025 Sales Top Estimates, Stock Soars
Mediterranean fast-casual restaurant chain CAVA (NYSE:CAVA) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 20.9% year on year to $275 million. Its GAAP profit of $0.04 per share was $0.01 above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Revolve (NYSE:RVLV) Delivers Strong Q4 CY2025 Numbers
Online fashion retailer Revolve (NASDAQ:RVLV) announced better-than-expected revenue in Q4 CY2025, with sales up 10.4% year on year to $324.4 million. Its GAAP profit of $0.26 per share was 57.8% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
2 Millionaire-Maker Quantum Computing Stocksfool.com
A decade from now, the quantum computing market could be huge.
Via The Motley Fool · February 24, 2026
WDAY Shares Tumble Nearly 8% After-Hours On Weak FY27 Guidancestocktwits.com
Workday Inc. reported revenues of $2.53 billion, an increase of 14.5% from the same period last year, and marginally above Wall Street estimates of $2.52 billion, as per data from Fiscal.ai.
Via Stocktwits · February 24, 2026
Apple CEO Tim Cook Says If You Look at Your Phone More Than Someone's Eyes, 'You're Doing The Wrong Thing'benzinga.com
Via Benzinga · February 24, 2026
A Canadian Dividend Stock Down 50% to Buy Foreverhttps://www.fool.ca/2026/02/24/a-canadian-dividend-stock-down-50-to-buy-forever/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=ea6ab21f-283f-4953-a7d7-17eb2dedafe8
Down 50% from all-time highs, the TSX dividend stock offers significant upside potential to shareholders right now.
Via The Motley Fool · February 24, 2026
The Secrets That TFSA Millionaires Knowhttps://www.fool.ca/2026/02/24/the-secrets-that-tfsa-millionaires-know-2/?source=iedfctemc0000001&utm_source=financialcontent&utm_campaign=CA_All_Articles&utm_content=Articles&utm_medium=rssfeed&lidx=0&referring_guid=f0be0369-f904-4261-b504-b765afc15552
Unlock the power of your TFSA and learn how to build tax-free wealth with smart savings strategies in Canada.
Via The Motley Fool · February 24, 2026
Marqeta (NASDAQ:MQ) Posts Better-Than-Expected Sales In Q4 CY2025 But Stock Drops
Payment technology company Marqeta (NASDAQ:MQ) announced better-than-expected revenue in Q4 CY2025, with sales up 26.7% year on year to $172.1 million. The company expects next quarter’s revenue to be around $164.1 million, close to analysts’ estimates. Its GAAP loss of $0 per share was $0.01 above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Are You Falling for These 3 Medicare Myths?fool.com
Don't let bad information destroy your retirement finances.
Via The Motley Fool · February 24, 2026
Lucid Stock Slides On Mixed Q4 Earnings, EV Maker Sets 2026 Production Targetbenzinga.com
Lucid reports financial results for the fourth quarter after the market close on Tuesday. Here's a look at the key details from the print.
Via Benzinga · February 24, 2026
LCID Stock Falls After-Hours On Wider-Than-Expected Q4 Lossstocktwits.com
The company reported a Q4 loss per share of $3.62, higher than an estimated loss of $2.63 per share, according to data from Fiscal AI.
Via Stocktwits · February 24, 2026
Workday (NASDAQ:WDAY) Reports Q4 CY2025 In Line With Expectations But Stock Drops
Enterprise software company Workday (NASDAQ:WDAY) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 14.5% year on year to $2.53 billion. Its non-GAAP profit of $2.47 per share was 6.4% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
Flywire (NASDAQ:FLYW) Beats Expectations in Strong Q4 CY2025, Stock Jumps 11.9%
Global payments company Flywire (NASDAQ:FLYW) announced better-than-expected revenue in Q4 CY2025, with sales up 39.7% year on year to $157.5 million. Its GAAP loss of $0 per share was $0.01 above analysts’ consensus estimates.
Via StockStory · February 24, 2026
FirstSolar Stock Plunges 12% — Why Such A Selloff?stocktwits.com
The company reported fourth quarter net income per diluted share of $4.84, which was well below analysts’ estimates of $5.24 per share, according to data from fiscal.ai.
Via Stocktwits · February 24, 2026
Here's Why Lucid Group Stock Is a Sell Before 2027fool.com
EV success will depend on AI innovation.
Via The Motley Fool · February 24, 2026
Workday Retreats As Fiscal 2027 Guidance Falls Short Amid CEO's Returninvestors.com
Workday stock fell after the enterprise software maker's fiscal 2027 sales guidance underwhelmed amid a recent CEO change.
Via Investor's Business Daily · February 24, 2026
Boston Beer (NYSE:SAM) Reports Q4 CY2025 In Line With Expectations
Beer company Boston Beer (NYSE:SAM) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 4.1% year on year to $385.7 million. Its GAAP loss of $2.12 per share was 15.3% above analysts’ consensus estimates.
Via StockStory · February 24, 2026
First Solar Stock Craters As Q4 Earnings Miss Estimatesbenzinga.com
Here's a detailed look inside the Q4 earnings report from First Solar.
Via Benzinga · February 24, 2026
Zeta Global (NYSE:ZETA) Delivers Impressive Q4 CY2025, Growth To Accelerate Next Year
Marketing technology company Zeta Global (NYSE:ZETA) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 25.4% year on year to $394.6 million. Guidance for next quarter’s revenue was optimistic at $370 million at the midpoint, 2.1% above analysts’ estimates.
Via StockStory · February 24, 2026
AbCellera Biologics Q4 Earnings Report: What Investors Need to Knowbenzinga.com
Via Benzinga · February 24, 2026
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 21.5% year on year to $211.6 million. On the other hand, the company’s full-year revenue guidance of $855 million at the midpoint came in 0.7% below analysts’ estimates. Its GAAP loss of $0.07 per share was 66.7% above analysts’ consensus estimates.
Via StockStory · February 24, 2026